Roche Klonopin approved for panic disorder April 9; titrating doses also cleared.
ROCHE KLONOPIN APPROVED FOR PANIC DISORDER APRIL 9 along with FDA approval of two new strength tablets, .125 mg and .25 mg, making it the second benzodiazepine for the indication. NDA 17-533/S-023 was deemed "approvable" by FDA Nov. 7, 1996. Pharmacia & Upjohn's benzodiazepine Xanax (alprazolam) carries a panic indication, as does SmithKline Beecham's selective serotonin reuptake inhibitor Paxil (paroxetine). Klonopin is marketed as an anticonvulsant.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth